NCT07174310 (PARAISO) is a Phase 3 clinical trial of Prasinezumab in Parkinson's Disease, sponsored by Hoffmann-La Roche.

Who is sponsoring NCT07174310?

NCT07174310 is sponsored by Hoffmann-La Roche.

What drugs are being tested in NCT07174310?

Interventions in NCT07174310: Prasinezumab, Placebo.

What condition does NCT07174310 study?

NCT07174310 studies Parkinson's Disease.

Is NCT07174310 still recruiting?

NCT07174310 is currently recruiting now. Last updated 6 April 2026.

Last reviewed 2026-04-06 · How we verify

NCT07174310: PARAISO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Recruiting now Phase 3 Last updated 6 April 2026

What this trial tests

Phase 3 trial testing Prasinezumab in Parkinson's Disease in 900 participants. Currently enrolling.

Timeline

24 November 2025

Primary endpoint
30 June 2029

30 June 2031

Quick facts

Lead sponsor	Hoffmann-La Roche
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	900
Start date	24 November 2025
Primary completion	30 June 2029
Estimated completion	30 June 2031
Sites	101 locations across Denmark, Italy, Austria, Taiwan, United Kingdom, Germany, Poland, Mexico

Drugs / interventions tested

Prasinezumab — full drug profile →
Placebo

Conditions studied

Parkinson's Disease — all drugs for Parkinson's Disease →

Sponsor

Hoffmann-La Roche — full company profile →

Who can join

Adults 50 to 85, any sex, with Parkinson's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.
Nikolcheva T, Pagano G, Anzures-Cabrera J, Trundell D, et al · · 2026 · PMID 42208564 · DOI 10.1016/s0140-6736(26)00865-2
Exidavnemab binds to aggregated α-synuclein in human brains affected by α-synucleinopathies.
Zachrisson O, Johannesson M, Söderberg L, Eriksson F, et al · · 2026 · PMID 41198458 · DOI 10.1016/j.neurot.2025.e00779

Verify or expand the search:

Other trials of Prasinezumab

Trials testing the same drug.

NCT04777331 — A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease · Phase 2 · active not recruiting

Other recruiting trials for Parkinson's Disease

Currently open trials in the same condition.

NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07330258 — A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite · recruiting
NCT07384429 — Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease · Phase 4 · recruiting
NCT07384442 — Effects of Targeted Temporal Interference Stimulation of Cerebellar Nuclei on Tremor and Gait Disturbance in Parkinson's · NA · recruiting
NCT06562569 — Non-invasive VNS for PD Gait · NA · recruiting

Other Hoffmann-La Roche trials

Trials by the same sponsor.

NCT07503340 — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous O · Phase 2 · not yet recruiting
NCT07298421 — A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in · Phase 3 · recruiting
NCT07059273 — A COPD Data Registry for Participants With Frequent Exacerbations · not yet recruiting
NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A · Phase 3 · recruiting
NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07174310 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoffmann-La Roche
Last refreshed: 6 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07174310.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing